Table 1.
Transition probabilities, utilities, and medical costs in the Markov model for THA
| Parameter | Value | Source |
|---|---|---|
| Mortality | ||
| Natural death | Varies by age and gender | US Census Bureau Life Expectancy Table [39] |
| Perioperative THA death | Varies by age and gender | Memtsoudis et al. [27] |
| Perioperative revision death | Age < 75 years: 0.003; age ≥ 75 years: 0.012 | Mota [29] |
| Revision | ||
| Early aseptic first revision | Varies by age and gender | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Late aseptic first revision | Varies by age and gender | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Early aseptic second revision | 0.0583 | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Late aseptic second revision | 0.022 | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Early infection first revision | Varies by age and gender | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Late infection first revision | Varies by age and gender | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Early infection second revision | 0.017 | Australian Orthopaedic Association National Joint Replacement Registry [1]; Parvizi et al. [32] |
| Late infection second revision | 0.006 | Australian Orthopaedic Association National Joint Replacement Registry [1]; Lie et al. [23] |
| Transitional probability of nonoperative treatment to more severe OA | ||
| More severe OA | 0.041 | Mota [29] |
| Utility | ||
| End-stage hip OA | Varies by gender | Value for males: 0.52; for females: 0.47; Mota [29] |
| Nonsurgery | Varies by gender | Value for males: 0.52; for females: 0.47; Mota [29] |
| More severe OA | 0.28 | Mota [29] |
| Initial post-THA | 0.74 | Mota [29]; current authors’ calculation |
| Successful post-THA | Varies by gender | Values for males: 0.83; for females: 0.8; Mota [29] |
| Post-first revision THA (early and late) | 0.64 | Mota [29] |
| Post-second THA revision | 0.58 | Mota [29]; current authors’ calculation |
| Annual direct medical costs | ||
| End-stage OA/nonsurgery/more severe OA | USD 12,815 | Current authors’ calculation |
| Initial post-THA | USD 38,965 | Current authors’ calculation |
| Successful THA | USD 12,225 | Base value: medical cost of end-stage OA USD 590; current authors’ calculation |
| First aseptic revision THA (early and late) | USD 57,141 | Current authors’ calculation |
| First infection revision THA (early and late) | USD 95,763 | Current authors’ calculation |
OA = osteoarthritis.